title: Management of bone metastases in breast cancer.
abstract: Patients with advanced breast cancer who develop bone metastases suffer an ongoing risk of skeletal complications that can have a significant impact on their quality of life (QoL). These complications include bone pain, pathologic fractures, spinal cord compression, and hypercalcemia of malignancy (HCM), a potentially life-threatening condition. Treatment options include radiotherapy to palliate bone pain and/or prevent impending fracture, orthopedic surgery to prevent or repair fractures, analgesics, and bisphosphonates, which can significantly reduce the risk of skeletal complications and delay their onset. Of the known bisphosphonates, zoledronic acid is the most potent. Since its regulatory approval in the United States and Europe in 2001, zoledronic acid (4 mg by 15-minute infusion) has become widely used and has replaced pamidronate (90 mg by 2-hour infusion) as the standard of care for treating bone metastases from breast cancer and bone lesions from multiple myeloma. Zoledronic acid has also demonstrated significant long-term benefits in randomized trials in prostate cancer and other solid tumors, whereas other bisphosphonates have failed. In long-term, phase III clinical testing, zoledronic acid provided significant treatment benefits beyond those of pamidronate in patients with breast cancer and demonstrated a safety profile comparable with pamidronate. Therefore, zoledronic acid is now recommended from the first diagnosis of bone metastasis. Other intravenous bisphosphonates include clodronate and ibandronate. Both are approved in Europe, but their efficacy relative to pamidronate and zoledronic acid is not known.
authors.affiliation: Penn State University, Milton S. Hershey Medical Center, College of Medicine, 500 University Drive, Hershey, PA 17033, USA. alipton@psu.edu
authors.forename: Allan
authors.initials: A
authors.lastname: Lipton
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D017326:Clinical Trials, Phase III as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D010166:Palliative Care; D000077268:Pamidronate; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3719-36
references.pmid: 12202673
references.citation: Ann Oncol. 2003 Sep;14 (9):1399-405
references.pmid: 12954579
references.citation: Clin J Oncol Nurs. 2003 Jul-Aug;7(4):403-8
references.pmid: 12929273
references.citation: J Clin Oncol. 2000 Mar;18(6):1378-91
references.pmid: 10715310
references.citation: J Clin Oncol. 2003 Aug 15;21(16):3150-7
references.pmid: 12915606
references.citation: Cancer. 2004 Jan 1;100(1):36-43
references.pmid: 14692022
references.citation: J Clin Oncol. 1999 Mar;17(3):846-54
references.pmid: 10071275
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1404-11
references.pmid: 12663734
references.citation: J Nucl Med. 2001 Jun;42(6):895-906
references.pmid: 11390554
references.citation: Support Care Cancer. 2001 Oct;9(7):545-51
references.pmid: 11680835
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3219-24
references.pmid: 12149294
references.citation: J Clin Oncol. 2001 Jan 1;19(1):10-7
references.pmid: 11134190
references.citation: Int J Cancer. 2001 Oct 15;94(2):153-6
references.pmid: 11668491
references.citation: J Clin Oncol. 1998 Jun;16(6):2038-44
references.pmid: 9626201
references.citation: Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S10-8
references.pmid: 12562046
references.citation: N Engl J Med. 1998 Aug 6;339(6):357-63
references.pmid: 9691101
references.citation: Clin Drug Investig. 2003;23(11):707-16
references.pmid: 17536884
references.citation: Calcif Tissue Int. 2003 Oct;73(4):315-8
references.pmid: 12874704
references.citation: Br J Radiol. 2003 Jan;76(901):69-75
references.pmid: 12595329
references.citation: J Clin Oncol. 2001 Jan 15;19(2):558-67
references.pmid: 11208851
references.citation: Crit Rev Oncol Hematol. 2002 Mar;41(3):317-25
references.pmid: 11880207
references.citation: Cancer. 2000 Mar 1;88(5):1082-90
references.pmid: 10699899
references.citation: Cancer Invest. 2002;20 Suppl 2:45-54
references.pmid: 12442349
references.citation: Expert Opin Emerg Drugs. 2003 Nov;8(2):469-88
references.pmid: 14662000
references.citation: Cancer. 2003 Oct 15;98(8):1735-44
references.pmid: 14534891
references.citation: Br J Haematol. 2001 Jun;113(4):1035-43
references.pmid: 11442499
references.citation: J Bone Miner Res. 1998 Apr;13(4):581-9
references.pmid: 9556058
references.citation: Cancer J. 2001 Sep-Oct;7(5):377-87
references.pmid: 11693896
references.citation: Cancer. 2003 Feb 1;97(3 Suppl):859-65
references.pmid: 12548587
references.citation: Cancer Treat Rev. 2001 Jun;27(3):165-76
references.pmid: 11417967
references.citation: J Clin Oncol. 2003 Nov 1;21(21):4042-57
references.pmid: 12963702
references.citation: J Clin Oncol. 2000 Jan;18(1):72-9
references.pmid: 10623695
references.citation: Am J Clin Oncol. 2002 Dec;25(6 Suppl 1):S3-9
references.pmid: 12562045
references.citation: Radiother Oncol. 2003 Oct;69(1):21-31
references.pmid: 14597353